The metabolic syndrome in HIV

Signe W Worm; Jens D Lundgren

doi:10.1016/j.beem.2010.10.018

The metabolic syndrome in HIV

Signe W Worm, Jens D Lundgren

LUKKET: Institut for Immunologi og Mikrobiologi

21 Citationer (Scopus)

Abstract

The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.

Originalsprog	Engelsk
Tidsskrift	Best Practice & Research: Clinical Endocrinology & Metabolism
Vol/bind	25
Udgave nummer	3
Sider (fra-til)	479-86
Antal sider	8
ISSN	1521-690X
DOI	https://doi.org/10.1016/j.beem.2010.10.018
Status	Udgivet - 1 jun. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.beem.2010.10.018

Citationsformater

@article{98662986f9af46b4a3e5749b01e95522,

title = "The metabolic syndrome in HIV",

abstract = "The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.",

author = "Worm, {Signe W} and Lundgren, {Jens D}",

year = "2011",

month = jun,

day = "1",

doi = "10.1016/j.beem.2010.10.018",

language = "English",

volume = "25",

pages = "479--86",

journal = "Best Practice and Research: Clinical Endocrinology and Metabolism",

issn = "1521-690X",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The metabolic syndrome in HIV

AU - Worm, Signe W

AU - Lundgren, Jens D

PY - 2011/6/1

Y1 - 2011/6/1

N2 - The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.

AB - The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.

U2 - 10.1016/j.beem.2010.10.018

DO - 10.1016/j.beem.2010.10.018

M3 - Journal article

C2 - 21663841

SN - 1521-690X

VL - 25

SP - 479

EP - 486

JO - Best Practice and Research: Clinical Endocrinology and Metabolism

JF - Best Practice and Research: Clinical Endocrinology and Metabolism

IS - 3

ER -

The metabolic syndrome in HIV

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater